GlassScriptPhysician profile
Sirithepphavanh Oliver
NPI 1013299197
$18,766.51
in general payments reported to CMS, 2019-2025
15 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 89% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,181 · 2022: $8,193 · 2023: $7,665 · 2024: $591 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,550 · Travel and Lodging: $2,874 · Food and Beverage: $1,891 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,550.00 |
| Travel and Lodging | $2,874.36 |
| Food and Beverage | $1,890.57 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $10,195.18 | 2021-2024 | Zejula, Jemperli |
| Merck Sharp & Dohme LLC | $5,663.53 | 2022-2023 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $1,084.78 | 2021 | |
| Janssen Biotech, INC. | $570.36 | 2023-2025 | Rybrevant, Carvykti, Darzalex |
| Tempus Ai, INC | $181.06 | 2025 | Xt Cdx |
| Beone Medicines USA, INC. | $137.03 | 2025 | Tevimbra |
| Pharmacosmos Therapeutics INC. | $129.49 | 2025 | Cosela |
| Pfizer INC. | $125.00 | 2024 | |
| Abbvie INC. | $124.93 | 2025 | |
| Genmab U.S., INC. | $124.93 | 2024 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $108.44 | 2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $105.90 | 2025 | Opdivo |
| Seagen INC. | $91.21 | 2022 | |
| Agios Pharmaceuticals, INC. | $74.67 | 2024 | Pyrukynd |
| Eisai INC. | $50.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sirithepphavanh Oliver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.